Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2024-11-28 DOI:10.3324/haematol.2024.286257

Lorenzo Falchi, Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L Bartlett, Antonio Salar, Joshua D Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Fabiola Bene Tchaleu, Linda Lundberg, Emmanuel Bachy

引用次数: 0

Abstract

Not available.

查看原文本刊更多论文

与其他皮质类固醇治疗方案相比，地塞米松在复发/难治性大B细胞淋巴瘤患者使用格洛菲坦单抗前可减少细胞因子释放综合征的发生频率和强度。

不详。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.